NO20075753L - Polymyxin B analogs for LPS detoxification - Google Patents

Polymyxin B analogs for LPS detoxification

Info

Publication number
NO20075753L
NO20075753L NO20075753A NO20075753A NO20075753L NO 20075753 L NO20075753 L NO 20075753L NO 20075753 A NO20075753 A NO 20075753A NO 20075753 A NO20075753 A NO 20075753A NO 20075753 L NO20075753 L NO 20075753L
Authority
NO
Norway
Prior art keywords
dimers
parallel
lps
peptide
saep
Prior art date
Application number
NO20075753A
Other languages
Norwegian (no)
Inventor
Massimo Porro
Tino Krell
Noelle Mistretta
Monique Moreau
Alessandro Rustici
Massimo Velucchi
Original Assignee
Biosynth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05300270A external-priority patent/EP1712559A1/en
Application filed by Biosynth filed Critical Biosynth
Publication of NO20075753L publication Critical patent/NO20075753L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof

Abstract

Det beskrives SAEP II peptid dimerer som etterligner polymyksin B blant annet når det gjelder evnen til ikke-kovalent og binde lipopolysakkarid (gramnegative bakterier) med høy affinitet og derfor å detoksifisere LPS slik polymyksin B gjør. Den dimere struktur opprettholdes ved hjelp av et par disulfidbindinger som involverer de to cysteinrester som er til stede i peptidsekvens som ikke overskrider 17 aminosyrer og i det vesentlige omfatter kationiske og hydrofobe aminosyrerester. I dimerene ifølge oppfinnelsen kan peptidene ha en parallell eller anti-parallell orientering. Som eksempel består en dimer ifølge oppfinnelsen av et peptid med formelen NH2-Lys-Thr-Lys-Cys1-Lys-Phe-Leu-Leu-Lcu-Cys2-COOH enten i parallell eller anti-parallell dimer form. SAEP II dimerer er brukbare for terapi eller prevensjon av septisk sjokk og relaterte forstyrrelser som genereres av gramnegativ bakterieinfeksjon. Oppfinnelsen angår også LPS-peptidkompleks der LPS og SAEP II dimerer ikke-kovalent er bundet. Disse komplekser er nyttige som vaksinemidler mot gramnegativ bakterieinfeksjon.SAEP II peptide dimers are described which mimic polymyxin B, inter alia, in the ability to non-covalently bind high-affinity lipopolysaccharide (Gram-negative bacteria) and therefore to detoxify LPS as polymyxin B does. The dimeric structure is maintained by a pair of disulfide bonds involving the two cysteine residues present in a peptide sequence not exceeding 17 amino acids and substantially comprising cationic and hydrophobic amino acid residues. In the dimers of the invention, the peptides may have a parallel or anti-parallel orientation. By way of example, a dimer according to the invention consists of a peptide of the formula NH2-Lys-Thr-Lys-Cys1-Lys-Phe-Leu-Leu-Lcu-Cys2-COOH either in parallel or anti-parallel dimer form. SAEP II dimers are useful for the therapy or prevention of septic shock and related disorders generated by gram-negative bacterial infection. The invention also relates to LPS-peptide complex where LPS and SAEP II dimers are non-covalently bound. These complexes are useful as vaccines for gram-negative bacterial infection.

NO20075753A 2005-04-11 2007-11-09 Polymyxin B analogs for LPS detoxification NO20075753L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05300270A EP1712559A1 (en) 2005-04-11 2005-04-11 Polymyxin B analogs for LPS detoxification
EP05300319 2005-04-26
PCT/EP2006/003237 WO2006108586A2 (en) 2005-04-11 2006-04-10 Polymyxin b analogs for lps detoxification

Publications (1)

Publication Number Publication Date
NO20075753L true NO20075753L (en) 2007-11-09

Family

ID=36968822

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075753A NO20075753L (en) 2005-04-11 2007-11-09 Polymyxin B analogs for LPS detoxification

Country Status (11)

Country Link
EP (1) EP1871787A2 (en)
JP (1) JP2008537749A (en)
KR (1) KR20070118646A (en)
AU (1) AU2006233634A1 (en)
BR (1) BRPI0610701A2 (en)
CA (1) CA2603850A1 (en)
IL (1) IL186322A0 (en)
MX (1) MX2007012457A (en)
NO (1) NO20075753L (en)
NZ (1) NZ561374A (en)
WO (1) WO2006108586A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5275982B2 (en) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
EP2429658B1 (en) 2009-05-14 2016-04-20 Sanofi Pasteur Method for adjuvating the lipopolysaccharide (LPS) of gram-negative bacteria
EP2430151B1 (en) 2009-05-14 2014-06-18 Sanofi Pasteur Meningococcal vaccine constituted of lipooligosaccharides from modified immunotype l6 neisseria meninigitidis
TWI548746B (en) * 2009-08-06 2016-09-11 英特威特國際股份有限公司 A vaccine directed against porcine pleuropneumonia and a method to obtain such a vaccine
AR113430A1 (en) * 2017-12-22 2020-04-29 Hanmi Pharm Ind Co Ltd THERAPEUTIC ENZYMATIC FUSION PROTEIN THAT HAS A NEW STRUCTURE AND ITS USE
WO2021187928A1 (en) * 2020-03-20 2021-09-23 단디바이오사이언스 주식회사 Composition and kit for removing lipopolysaccharide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5371186A (en) * 1991-02-11 1994-12-06 Biosynth S.R.L. Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
WO2004052394A1 (en) * 2002-12-06 2004-06-24 Biosynth S.R.L. Broad-spectrum lps based vaccines of unencapsulated strains of haemophilus influenzae and other pathogenic species of gram-negative bacteria

Also Published As

Publication number Publication date
KR20070118646A (en) 2007-12-17
CA2603850A1 (en) 2006-10-19
BRPI0610701A2 (en) 2010-07-20
AU2006233634A1 (en) 2006-10-19
WO2006108586A2 (en) 2006-10-19
IL186322A0 (en) 2008-01-20
MX2007012457A (en) 2007-12-10
NZ561374A (en) 2009-02-28
EP1871787A2 (en) 2008-01-02
WO2006108586A3 (en) 2006-12-14
JP2008537749A (en) 2008-09-25

Similar Documents

Publication Publication Date Title
NO20075753L (en) Polymyxin B analogs for LPS detoxification
EA200100968A1 (en) DIMERIC COMPOUNDS AND THEIR APPLICATION AS NEURAMINIDASE INHIBITORS
DE60238993D1 (en) HYBRID AND TANDEM PROTEINS FROM NEISSERIA SP
NO20045021L (en) Immunological methods and preparations for the treatment of Alzheimer's disease
NO20063026L (en) antibodies
NO20053773L (en) Parental peptide formulations for the treatment of systemic lupus erythematosus
CO6331292A2 (en) INSULIN COMPOUNDS LISPRO PEGILADA
ES2178000T3 (en) COMPOSITIONS AND METHODS TO TREAT INFECTIONS USING INDOLICIDINE ANALOGS.
NO20076056L (en) Methods for purifying FC region containing proteins
MY161664A (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
ATE544780T1 (en) HYBRID POLYPEPTIDES WITH INSERTED SEQUENCE MOTIFS AND THEIR USES
NO20070296L (en) Oligomeric peptides and their use in the treatment of HIV infections
MX2009013635A (en) Influenza inhibiting compositions and methods.
WO2005058959A3 (en) Treatment of viral infections
HK1093308A1 (en) Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock
RU2007115411A (en) HSP60 PEPTIDES AND THEIR APL-DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS
DK2044125T3 (en) Compositions and Methods for Administration of Activated Anti-Ras Antibodies into Cells
KR910002899A (en) Blood Regulatory Peptides
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
JP2015519342A (en) Bioactive peptide complex
WO2004018499A3 (en) Synthetic heparin-binding growth factor analogs
JP2008537749A5 (en)
BR0313019A (en) Compounds that bind to p-selectin
AR053355A1 (en) POLYMIXIN B ANALOGS FOR LPS DETOXIFICATION
TH84559B (en) An analogue of polymycin B for LPS toxic decomposition.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application